Syneos Health EPS beats by $0.09, beats on revenue
Syneos Health (NASDAQ:SYNH): Q2 Non-GAAP EPS of $0.58 beats by $0.09; GAAP EPS of $0.04 beats by $0.05. Revenue of $1.01B (-13.7% Y/Y) beats by $10M. Press
seekingalpha · 1天前
Syneos Health (SYNH) Q2 Earnings and Revenues Surpass Estimates
Syneos Health (SYNH) delivered earnings and revenue surprises of 20.83% and 0.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1天前
Syneos Health Reports Second Quarter 2020 Results
Highlights * GAAP revenue of $1,013.4 million for the three months ended June 30, 2020, representing a decline of 13.1%, 13.3% on an adjusted basis, and 12.8% on a constant currency adjusted basis compared to the same period in 2019. * Net new business awa
GlobeNewswire · 1天前
Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Did Hedge Funds Make The Right Call On Syneos Health, Inc. (SYNH) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional invest
Insider Monkey · 07/20 15:02
Syneos Health Signs New Service Agreement With Pfizer
MORRISVILLE, N.C., July 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new three-year
Benzinga · 07/13 12:34
Syneos Health Signs New Service Agreement With Pfizer
MORRISVILLE, N.C., July 13, 2020 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new.
GlobeNewswire · 07/13 12:30
Notable Insider Buys: Acceleron, Continental And Syneos Health
Syneos Health Inc.是一家提供完全集成的生物制药解决方案公司。公司通过其合同研究组织（CRO）和合同商业组织（CCO）提供独立和集成的生物制药产品开发解决方案，范围从早期（第一阶段）临床试验到生物制药产品的全面商业化。它汇集了大约24,000名临床和商务专业人员，能够为110多个国家/地区的客户提供支持，共同分享见解，利用最新技术并应用先进的业务实践为患者提供重要的疗法。